Status:
COMPLETED
Opioid Analgesic Reduction Study (OARS) - Pilot
Lead Sponsor:
Rutgers, The State University of New Jersey
Collaborating Sponsors:
University of Illinois at Chicago
University of Maryland, Baltimore
Conditions:
Post Operative Pain
Eligibility:
All Genders
18-99 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to test protocols being developed for the conduct of a large sale multi-site clinical trial which will compare opioids to non-opioids for managing post-surgical impacted 3...
Detailed Description
A double-blind stratified randomized clinical trial is being conduct on the management of post-surgical pain after extraction of impacted third mandibular molars Subjects will be randomly assigned to ...
Eligibility Criteria
Inclusion
- Adult men and non-pregnant women who are at least 18 years of age, who are able to refrain from driving or operating heavy machinery while taking the study medication will be able to participate.
- Subjects who are English speaking and are able to provide consent will be considered.
- Subjects must be in generally good health and able to take ibuprofen, paracetamol (acetaminophen), and hydrocodone.
Exclusion
- Subjects who self-report the following history will be excluded from participating:
- Individual under the age of 18
- History of gastrointestinal bleeding and/or peptic ulcer
- History of renal disease (excluding kidney stones)
- History of hepatic disease
- History of bleeding disorder
- History of respiratory depression
- Any prior respiratory effect of an opioid or other anesthetic drug that required respiratory support postoperatively
- Active or untreated asthma
- History of known allergic reaction to ibuprofen, acetaminophen, hydrocodone, and/or anesthesia
- Currently taking any of the following medications:
- CYP3A4 inhibitor, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), which may increase plasma concentrations of hydrocodone bitartrate and acetaminophen and prolong opioid adverse reactions, and which may cause potentially fatal respiratory depression
- CNS depressants.
- Consumes 3 or more alcoholic drinks every day and/or has a history of alcoholism
- History of drug or alcohol abuse (excludes marijuana use)
- Family history of drug or alcohol abuse in a first degree relative
- Has had one or more opioid prescription filled within the past 6 months
- Currently pregnant or lactating
- Patients would also be excluded due to any additional criteria that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study which includes:
- Prior participation in this study
- Inability or refusal to provide informed consent
Key Trial Info
Start Date :
July 6 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 26 2021
Estimated Enrollment :
53 Patients enrolled
Trial Details
Trial ID
NCT05283499
Start Date
July 6 2020
End Date
March 26 2021
Last Update
June 6 2023
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Illinois Chicago
Chicago, Illinois, United States, 60607
2
University of Maryland
Baltimore, Maryland, United States, 21201
3
University of Michigan
Ann Arbor, Michigan, United States, 48109
4
Rutgers University
Newark, New Jersey, United States, 07103